⌘K

Login Start Free

Home/Filings/4/0001628280-23-036462

4//SEC Filing

Ragan Paula 4

Accession 0001628280-23-036462

CIK 0001501697other

View on SEC.gov Company Profile

Filed

Nov 1, 8:00 PM ET

Accepted

Nov 2, 4:58 PM ET

Size

5.0 KB

Accession

0001628280-23-036462

Insider Transaction Report

Form 4

Period: 2023-10-31

X4 Pharmaceuticals, IncXFOR

DirectorPresident and CEO

Transactions

Award
Common Stock
2023-10-31+532,081→ 1,075,878 total

Footnotes (1)

[F1]Represents shares earned upon the vesting of performance-based restricted stock units. The Compensation Committee of the Board of Directors of the Issuer certified the achievement of a performance condition, which occurs upon FDA acceptance of a new drug application for mavorixafor.

Documents

1 file

4
wk-form4_1698958692.xmlPrimary
FORM 4

Issuer

X4 Pharmaceuticals, Inc

CIK 0001501697

Entity typeother

Related Parties

1

filerCIK 0001769914

Filing Metadata

Form type: 4
Filed: Nov 1, 8:00 PM ET
Accepted: Nov 2, 4:58 PM ET
Size: 5.0 KB

View on SEC.gov